nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—parotid gland—salivary gland cancer	0.0136	0.085	CbGeAlD
Thalidomide—NFKB1—saliva-secreting gland—salivary gland cancer	0.013	0.0814	CbGeAlD
Thalidomide—FGFR2—neck—salivary gland cancer	0.0126	0.0783	CbGeAlD
Thalidomide—NFKB1—connective tissue—salivary gland cancer	0.012	0.0748	CbGeAlD
Thalidomide—CRBN—parotid gland—salivary gland cancer	0.0114	0.0712	CbGeAlD
Thalidomide—CRBN—saliva-secreting gland—salivary gland cancer	0.0109	0.0682	CbGeAlD
Thalidomide—FGFR2—saliva-secreting gland—salivary gland cancer	0.00979	0.0611	CbGeAlD
Thalidomide—FGFR2—connective tissue—salivary gland cancer	0.009	0.0562	CbGeAlD
Thalidomide—NFKB1—lymphoid tissue—salivary gland cancer	0.00876	0.0547	CbGeAlD
Thalidomide—TNF—lymph node—salivary gland cancer	0.00867	0.0541	CbGeAlD
Thalidomide—FGFR2—epithelium—salivary gland cancer	0.00854	0.0533	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—salivary gland cancer	0.00734	0.0458	CbGeAlD
Thalidomide—NFKB1—lymph node—salivary gland cancer	0.00494	0.0308	CbGeAlD
Thalidomide—CRBN—lymph node—salivary gland cancer	0.00414	0.0259	CbGeAlD
Thalidomide—CYP1A1—parotid gland—salivary gland cancer	0.0037	0.0231	CbGeAlD
Thalidomide—CYP1A1—epithelium—salivary gland cancer	0.00309	0.0193	CbGeAlD
Thalidomide—PTGS1—connective tissue—salivary gland cancer	0.00286	0.0179	CbGeAlD
Thalidomide—PTGS2—connective tissue—salivary gland cancer	0.00273	0.0171	CbGeAlD
Thalidomide—PTGS1—epithelium—salivary gland cancer	0.00272	0.0169	CbGeAlD
Thalidomide—PTGS2—epithelium—salivary gland cancer	0.0026	0.0162	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—salivary gland cancer	0.00217	0.0135	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—salivary gland cancer	0.002	0.0125	CbGeAlD
Thalidomide—CYP1A1—lymph node—salivary gland cancer	0.00134	0.00838	CbGeAlD
Thalidomide—PTGS1—lymph node—salivary gland cancer	0.00118	0.00736	CbGeAlD
Thalidomide—PTGS2—lymph node—salivary gland cancer	0.00113	0.00704	CbGeAlD
Thalidomide—NFKB1—Immune System—FBXW7—salivary gland cancer	0.000278	0.000331	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—salivary gland cancer	0.000278	0.000331	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—salivary gland cancer	0.000278	0.000331	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—salivary gland cancer	0.000278	0.000331	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ISYNA1—salivary gland cancer	0.000277	0.00033	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CREBBP—salivary gland cancer	0.000276	0.000329	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—salivary gland cancer	0.000275	0.000328	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—salivary gland cancer	0.000273	0.000325	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—salivary gland cancer	0.000272	0.000324	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—HRAS—salivary gland cancer	0.000271	0.000323	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGFR4—salivary gland cancer	0.000268	0.000319	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—PIK3CA—salivary gland cancer	0.000266	0.000317	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FBXW7—salivary gland cancer	0.000264	0.000314	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—EP300—salivary gland cancer	0.000262	0.000312	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—salivary gland cancer	0.000259	0.000309	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—salivary gland cancer	0.000259	0.000309	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAML3—salivary gland cancer	0.000258	0.000307	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—HRAS—salivary gland cancer	0.000257	0.000306	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—salivary gland cancer	0.000256	0.000305	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MARCKS—salivary gland cancer	0.000254	0.000303	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—salivary gland cancer	0.00025	0.000298	CbGpPWpGaD
Thalidomide—FGFR2—Disease—JAG1—salivary gland cancer	0.000248	0.000296	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGFR4—salivary gland cancer	0.000247	0.000295	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGF16—salivary gland cancer	0.000247	0.000294	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—salivary gland cancer	0.000246	0.000293	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CREBBP—salivary gland cancer	0.000244	0.000291	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FBXW7—salivary gland cancer	0.000243	0.00029	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—salivary gland cancer	0.000243	0.00029	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PHGDH—salivary gland cancer	0.000243	0.000289	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MARCKS—salivary gland cancer	0.000239	0.000285	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MARCKS—salivary gland cancer	0.000239	0.000284	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PYGB—salivary gland cancer	0.000236	0.000282	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF16—salivary gland cancer	0.000235	0.000279	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FOXO3—salivary gland cancer	0.000234	0.000279	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ST3GAL4—salivary gland cancer	0.000234	0.000278	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CDH1—salivary gland cancer	0.000233	0.000277	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NOTCH1—salivary gland cancer	0.000232	0.000277	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CREBBP—salivary gland cancer	0.000232	0.000276	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—salivary gland cancer	0.000229	0.000273	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	0.000227	0.00027	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ISYNA1—salivary gland cancer	0.000227	0.00027	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MARCKS—salivary gland cancer	0.000226	0.000269	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PYGB—salivary gland cancer	0.000223	0.000265	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FOXO3—salivary gland cancer	0.000222	0.000265	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—salivary gland cancer	0.000222	0.000265	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PYGB—salivary gland cancer	0.000222	0.000264	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ST3GAL4—salivary gland cancer	0.000222	0.000264	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CDH1—salivary gland cancer	0.000221	0.000263	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	0.00022	0.000261	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—PIK3CA—salivary gland cancer	0.000219	0.000261	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—PIK3CA—salivary gland cancer	0.000216	0.000257	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAML2—salivary gland cancer	0.000215	0.000256	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AQP1—salivary gland cancer	0.000212	0.000253	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CREBBP—salivary gland cancer	0.000211	0.000251	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PYGB—salivary gland cancer	0.00021	0.00025	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ISYNA1—salivary gland cancer	0.000207	0.000246	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—salivary gland cancer	0.000206	0.000245	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FOXO3—salivary gland cancer	0.000205	0.000245	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—PIK3CA—salivary gland cancer	0.000205	0.000244	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAML2—salivary gland cancer	0.000204	0.000243	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—salivary gland cancer	0.000203	0.000242	CbGpPWpGaD
Thalidomide—PTGS2—Disease—DTX4—salivary gland cancer	0.000201	0.00024	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—salivary gland cancer	0.0002	0.000238	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—salivary gland cancer	0.000199	0.000238	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—salivary gland cancer	0.000199	0.000237	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PHGDH—salivary gland cancer	0.000193	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAP2K2—salivary gland cancer	0.000191	0.000228	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—salivary gland cancer	0.00019	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—salivary gland cancer	0.000189	0.000225	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EP300—salivary gland cancer	0.000188	0.000224	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ST3GAL4—salivary gland cancer	0.000186	0.000221	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MARCKS—salivary gland cancer	0.000185	0.00022	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JAG1—salivary gland cancer	0.000183	0.000218	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGFR4—salivary gland cancer	0.000183	0.000217	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAP2K2—salivary gland cancer	0.000182	0.000216	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PHGDH—salivary gland cancer	0.000181	0.000216	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PHGDH—salivary gland cancer	0.000181	0.000216	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FBXW7—salivary gland cancer	0.00018	0.000214	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—salivary gland cancer	0.000177	0.00021	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ISYNA1—salivary gland cancer	0.000177	0.00021	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ST3GAL4—salivary gland cancer	0.000175	0.000208	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PTEN—salivary gland cancer	0.000174	0.000208	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ST3GAL4—salivary gland cancer	0.000174	0.000208	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JAG1—salivary gland cancer	0.000174	0.000207	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGFR4—salivary gland cancer	0.000173	0.000206	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PYGB—salivary gland cancer	0.000172	0.000204	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PHGDH—salivary gland cancer	0.000171	0.000204	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FBXW7—salivary gland cancer	0.00017	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AQP1—salivary gland cancer	0.000168	0.000201	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MARCKS—salivary gland cancer	0.000168	0.000201	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NUP62—salivary gland cancer	0.000168	0.0002	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAP2K2—salivary gland cancer	0.000168	0.0002	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PTEN—salivary gland cancer	0.000167	0.000199	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—VCAN—salivary gland cancer	0.000167	0.000199	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF16—salivary gland cancer	0.000166	0.000198	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EP300—salivary gland cancer	0.000166	0.000198	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PTEN—salivary gland cancer	0.000165	0.000197	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ST3GAL4—salivary gland cancer	0.000165	0.000196	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NUP62—salivary gland cancer	0.00016	0.00019	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PTEN—salivary gland cancer	0.000159	0.000189	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AQP1—salivary gland cancer	0.000159	0.000189	CbGpPWpGaD
Thalidomide—PTGS2—Disease—VCAN—salivary gland cancer	0.000158	0.000188	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AQP1—salivary gland cancer	0.000158	0.000188	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EP300—salivary gland cancer	0.000158	0.000188	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PYGB—salivary gland cancer	0.000157	0.000186	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FOXO3—salivary gland cancer	0.000152	0.00018	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AQP1—salivary gland cancer	0.00015	0.000178	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	0.000147	0.000174	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAML2—salivary gland cancer	0.000145	0.000172	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MARCKS—salivary gland cancer	0.000144	0.000171	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FOXO3—salivary gland cancer	0.000144	0.000171	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EP300—salivary gland cancer	0.000143	0.000171	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CREBBP—salivary gland cancer	0.000142	0.000169	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDH1—salivary gland cancer	0.000141	0.000168	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	0.00014	0.000167	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PHGDH—salivary gland cancer	0.00014	0.000167	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOTCH1—salivary gland cancer	0.000137	0.000164	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	0.000136	0.000162	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CREBBP—salivary gland cancer	0.000135	0.000161	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ST3GAL4—salivary gland cancer	0.000135	0.00016	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDH1—salivary gland cancer	0.000134	0.000159	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PYGB—salivary gland cancer	0.000134	0.000159	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NUP62—salivary gland cancer	0.000134	0.000159	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—VCAN—salivary gland cancer	0.000133	0.000158	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—salivary gland cancer	0.000129	0.000153	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PHGDH—salivary gland cancer	0.000128	0.000152	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NUP62—salivary gland cancer	0.000126	0.00015	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NUP62—salivary gland cancer	0.000125	0.000149	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—VCAN—salivary gland cancer	0.000125	0.000149	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CREBBP—salivary gland cancer	0.000125	0.000148	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—VCAN—salivary gland cancer	0.000125	0.000148	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAP2K2—salivary gland cancer	0.000124	0.000147	CbGpPWpGaD
Thalidomide—PTGS2—Disease—JAG1—salivary gland cancer	0.000123	0.000147	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PIK3CA—salivary gland cancer	0.000123	0.000146	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR4—salivary gland cancer	0.000123	0.000146	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ST3GAL4—salivary gland cancer	0.000123	0.000146	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AQP1—salivary gland cancer	0.000122	0.000146	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FBXW7—salivary gland cancer	0.000121	0.000144	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NUP62—salivary gland cancer	0.000119	0.000141	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PIK3CA—salivary gland cancer	0.000118	0.000141	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—VCAN—salivary gland cancer	0.000118	0.00014	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAP2K2—salivary gland cancer	0.000117	0.00014	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PIK3CA—salivary gland cancer	0.000117	0.000139	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	0.000116	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—salivary gland cancer	0.000114	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PIK3CA—salivary gland cancer	0.000112	0.000133	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AQP1—salivary gland cancer	0.000112	0.000133	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—salivary gland cancer	0.000109	0.00013	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PHGDH—salivary gland cancer	0.000109	0.00013	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—salivary gland cancer	0.000108	0.000129	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ST3GAL4—salivary gland cancer	0.000105	0.000125	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	0.000105	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—salivary gland cancer	0.000104	0.000123	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	0.000103	0.000123	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FOXO3—salivary gland cancer	0.000102	0.000121	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—salivary gland cancer	0.000102	0.000121	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH1—salivary gland cancer	0.000101	0.000121	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	9.98e-05	0.000119	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—salivary gland cancer	9.82e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NUP62—salivary gland cancer	9.7e-05	0.000116	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—salivary gland cancer	9.68e-05	0.000115	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—salivary gland cancer	9.63e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—VCAN—salivary gland cancer	9.63e-05	0.000115	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH1—salivary gland cancer	9.62e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AQP1—salivary gland cancer	9.53e-05	0.000114	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CREBBP—salivary gland cancer	9.19e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—salivary gland cancer	9.19e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—salivary gland cancer	8.89e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NUP62—salivary gland cancer	8.85e-05	0.000105	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—VCAN—salivary gland cancer	8.78e-05	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CREBBP—salivary gland cancer	8.72e-05	0.000104	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—salivary gland cancer	8.48e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	8.45e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAP2K2—salivary gland cancer	8.33e-05	9.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	8.31e-05	9.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	7.92e-05	9.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	7.7e-05	9.17e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NUP62—salivary gland cancer	7.56e-05	9e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—VCAN—salivary gland cancer	7.5e-05	8.93e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	7.38e-05	8.79e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	7.37e-05	8.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—salivary gland cancer	7.16e-05	8.53e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	7.03e-05	8.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOTCH1—salivary gland cancer	6.82e-05	8.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—salivary gland cancer	6.8e-05	8.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—salivary gland cancer	6.8e-05	8.09e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—salivary gland cancer	6.63e-05	7.89e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	6.58e-05	7.84e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—salivary gland cancer	6.56e-05	7.82e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CREBBP—salivary gland cancer	6.53e-05	7.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—salivary gland cancer	6.45e-05	7.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—salivary gland cancer	6.29e-05	7.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—salivary gland cancer	6.28e-05	7.47e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—salivary gland cancer	6.26e-05	7.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—salivary gland cancer	6.23e-05	7.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CREBBP—salivary gland cancer	6.19e-05	7.37e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	6.03e-05	7.18e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—salivary gland cancer	5.94e-05	7.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	5.86e-05	6.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—salivary gland cancer	5.81e-05	6.91e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	5.75e-05	6.85e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	5.5e-05	6.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	5.25e-05	6.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	5.2e-05	6.19e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CREBBP—salivary gland cancer	5.18e-05	6.17e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CREBBP—salivary gland cancer	4.88e-05	5.81e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CREBBP—salivary gland cancer	4.87e-05	5.79e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	4.7e-05	5.6e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—salivary gland cancer	4.66e-05	5.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—salivary gland cancer	4.63e-05	5.51e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CREBBP—salivary gland cancer	4.6e-05	5.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	4.48e-05	5.34e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—salivary gland cancer	4.48e-05	5.34e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—salivary gland cancer	4.44e-05	5.29e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—salivary gland cancer	4.42e-05	5.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—salivary gland cancer	4.39e-05	5.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—salivary gland cancer	4.28e-05	5.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	4.26e-05	5.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—salivary gland cancer	4.25e-05	5.06e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—salivary gland cancer	4.21e-05	5.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—salivary gland cancer	4.07e-05	4.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	3.88e-05	4.62e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CREBBP—salivary gland cancer	3.76e-05	4.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—salivary gland cancer	3.7e-05	4.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—salivary gland cancer	3.53e-05	4.2e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—salivary gland cancer	3.48e-05	4.15e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—salivary gland cancer	3.48e-05	4.14e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CREBBP—salivary gland cancer	3.43e-05	4.08e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—salivary gland cancer	3.32e-05	3.95e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	3.32e-05	3.95e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—salivary gland cancer	3.31e-05	3.95e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—salivary gland cancer	3.29e-05	3.91e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—salivary gland cancer	3.28e-05	3.91e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—salivary gland cancer	3.13e-05	3.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—salivary gland cancer	3.12e-05	3.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CREBBP—salivary gland cancer	2.93e-05	3.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—salivary gland cancer	2.88e-05	3.43e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—salivary gland cancer	2.69e-05	3.2e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—salivary gland cancer	2.61e-05	3.11e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—salivary gland cancer	2.56e-05	3.05e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—salivary gland cancer	2.46e-05	2.93e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—salivary gland cancer	2.45e-05	2.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—salivary gland cancer	2.45e-05	2.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—salivary gland cancer	2.34e-05	2.78e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—salivary gland cancer	2.32e-05	2.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—salivary gland cancer	2.09e-05	2.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—salivary gland cancer	2e-05	2.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—salivary gland cancer	1.9e-05	2.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—salivary gland cancer	1.73e-05	2.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—salivary gland cancer	1.48e-05	1.76e-05	CbGpPWpGaD
